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Connective tissue growth factor (CTGF)/CCN family member 2 (CCN2) is a CCN family member of matricellular
signaling modulators. It has been shown that CCN2/CTGF mediates cell adhesion, aggregation and migration in a
large variety of cell types, including vascular endothelial cells, fibroblasts, epithelial cells, aortic smooth muscle and
also pluripotent stem cells. Others matricellular proteins are capable of interacting with CCN2/CTGF to mediate its
function. Cell migration is a key feature for tumor cell invasion and metastasis. CCN2/CTGF seems to be a
prognostic marker for cancer. In addition, here we intend to discuss recent discoveries and a new strategy to
develop therapies against CCN2/CTGF, in order to treat cancer metastasis.
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Connective tissue growth factor (CTGF)/CCN2 family
member 2 (CCN2) was isolated from human endothelial
cells and outlines a secreted growth factor involved in
cell proliferation and chemotaxis as former described in
1991, by Dr Bradham et al. [1]. CCN2/CTGF has 349
amino acids and depending on post-translational modifi-
cations, CCN2/CTGF can be glycosylated, causing either
36 or 38 kDa, which appears as a double band on Western
immunoblotting [2]. In the same year, CCN2/CTGF
orthologous was described in mice and named Fisp-12
[3] or even other synonyms as βIG-M2, IGF-BP8, IGFBP-
rP2, HBGF-0.8, Hcs24 or ecogenin [4]. Since its identi-
fication, CCN2/CTGF’s role has been studied, in a large
variety of biological phenomena, especially in cell chemo-
taxis, migration, adhesion and cancer. Still in the nineties,
other proteins with the same domains were identified,
such as cysteine-rich 61 (Cyr61), nephroblastoma overex-
pressed (Nov), expressed in low-metastatic protein (Elm1/
Wisp-1), WNT1-inducible-signaling pathway protein-2
(Wisp-2) and WNT1-inducible-signaling pathway protein-
3 (Wisp-3) [5-9]. In the following decade, researches who
have had contributed to the understanding of these* Correspondence: diegopaguiar@gmail.com
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creted factors in the CCN family (CYR61/CTGF/NOV),
then called CCN1 (Cyr61), CCN2 (CTGF), CCN3 (Nov),
CCN4 (Wisp-1), CCN5 (Wisp-2), and CCN6 (Wisp-3)
[10]. These proteins share a multimodular structure, with
a N-terminal secretory signal followed by four conserved
domains with homologies to insulin-like growth factor
binding proteins (Module I IGFBP), von willebrand factor
type C repeat (module II VWC), thrombospondin type I
repeat (Module III TSP) and a carboxy-terminal domain
(Module IV - CT) containing a cystine knot [absent in
CCN5] [10] (Figure 1).
Studies about the CCN family have been intensified in
the last years mainly to understand CCN2/CTGF function.
Several studies had also shown the relevance of each cata-
lytic domain on proliferation and chemotaxis [1], cell fate
[15], adhesion [16], and migration [17] in different cell
types and tissues. Several publications had also described
interactions of the CCN2/CTGF with extracellular matrix
proteins [18]. Ivkovic et al. in 2003 developed a knockout
mouse for CCN2/CTGF showing its role in extracellular
matrix remodeling and angiogenesis during chondrogene-
sis [19]. In addition, CCN2/CTGF knockout mice also
shows lower expression of metalloproteinase 9 and vascu-
lar endothelial growth factor (VEGF) in the growth plate.
These changes lead to skeletal dimorphism, with expanded
hypertrophic zones of CTGF mutant growth plates and aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Schematic representation of the CCN family structure.
The figure shows the current nomenclature (CCN family) and the
most used name along the last years. The CCN family domains are
arranged into modules as: IGF-binding/module I, VWC/module II,
TSP1/module II and CT-cystine knot/module IV. The size in each
domain of each CCN family member related to their biological
functions [11-14].
Figure 2 Interaction of CCN2/CTGF domains with other molecules. Th
surface receptors, extracellular matrix and growth factors, as Fibronectin, Pe
[28,29,31-35]. The left column shows the interaction between CCN2/CTGF w
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chondral ossification. This study was the first to demon-
strate the role of CCN2/CTGF during development.
CCN2/CTGF in cell adhesion and migration
The synthesis of CCN2/CTGF is highly inducible by
serum growth factors [20], cytokines [21], and environ-
mental stresses such as hypoxia [22] and molecular stretch
[23]. Well known inducers of CCN2/CTGF are transform-
ing growth factor beta (TGF-beta) and VEGF [24,25].
Despite researches willingness, a specific receptor for
CCN2/CTGF was never described. However, several
possible receptors for this growth factor had been inves-
tigated in CCN2/CTGF-mediated adhesion, migration
and chemotaxis, including integrins (α6β1,αvβ3,αMβ2,α5β1,
α6β1,αvβ3,αvβ5,αIIbβ3 and α3β1) [26,27], LRP1 and LRP6
[28,29], and HSPGs (co-receptor) [30] on cell membrane
(Figure 2). There are currently 89 published papers relat-
ing CCN2/CTGF to migration and adhesion, however, no
one has established a CCN2/CTGF receptor (Figure 3A).e right column shows the interaction between CCN2/CTGF with cell
rlecan, HSPGs, VEGF, TGF-β, BMP4, LRP1, Heparin, Syndecan-4
ith integrins [30,36-41].
Figure 3 Impact of CCN2/CTGF research in cancer metastasis. (A) Evaluation number of articles published per year that studied the role of
CCN2/CTGF on cell migration and metastasis (B) Cell migration and adhesion modulated by CCN2/CTGF. CCN2/CTGF promotes cells migration
and adhesion by binding to HSPGs and Integrins in cell surface. Integrins activation potentiates the phosphorylation of the ERK and P38, leading
to activation of F-actin and Paxillin resulting in actin reorganization [42]. The same pathway can stimulate FAK, PI-3 kinase ensuing phosphorylation of
the PKB/AKT and translocations of P27 to the nucleus that promotes the transcriptional control of RhoA, and thus enhances focal adhesion formation
and cellular migration [32].
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plained in part by its interactions with other molecules
in the extracellular domain. CCN2/CTGF binds to TGF-
beta through the VWC domain and enhances its binding
to TGF-beta receptor II, increasing its signaling [31,43].
A comparison of a pull of mRNA extracted from wild
type mouse embryonic fibroblast (MEFs) to MEFs deleted
for CCN2/CTGF(CTGF−/− MEF), both exposed to TGF-
beta, showed downregulation of several molecules in-
volved in matrix production and remodeling, cell adhe-
sion and contraction, such as: Filamin-β, β-Catenin andmatrix metalloproteinase-14. These results showed
CCN2/CTGF as a cofactor required to active cell adhe-
sion by TGF-beta [44]. Since CCN2/CTGF was described
to interact with other extracellular matrix proteins [45],
many efforts have been made to understand how can
CCN2/CTGF acts in cell adhesion and migration.
An efficient way to show the role of CCN2/CTGF in
cell adhesion was through the exposure of different cell
types to a CCN2/CTGF-rich substrate. Thus, it was
possible to show that cells exposed to CCN2/CTGF ad-
hered to substrate faster than cells exposed only to
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the role of CCN2/CTGF in cell adhesion, CCN2/CTGF
coated plastic surface and anti-CCN2/CTGF antibody
were used to measure cell adhesion of four different
cells types: vascular endothelial cells [HUVECs and hu-
man microvascular endothelial cells (HMVECs)], fibro-
blasts (NIH 3T3 and AKR2B), mink lung epithelial
(Mv1Lu) cells [26,45], and human platelets [48]. All results
showed that the absence of CCN2/CTGF prevents cell ad-
hesion. In addition, the CCN2/CTGF-mediated adhesion
occurs through interaction with other molecules, as fibro-
nectin and integrins, reviewed by Arnott et al in 2011 [48].
CCN2/CTGF CT-domain interacts with fibronectin and
enhances cell adhesion of chondrocytes through integrin
alpha5beta1 [49]. CCN2/CTGF promotes fibroblast adhe-
sion by binding to fibronectin, cell surface proteoglycans,
and integrins that potentiates the phosphorylation on focal
adhesion Kinase (FAK) and ERK and so enhances focal ad-
hesion formation and cell spreading by F-actin, Paxilin
and RhoA activation [32] (Figure 3B). Although these data
suggested that CCN2/CTGF is an adhesive molecule, this
property was never directly tested. However, a recent work
of our research group demonstrated that CCN2/CTGF is
not an adhesive molecule itself.
For the first time optical tweezers technique was used to
measure the adhesion strength of different molecules. Ini-
tially, It was observed that CCN2/CTGF induced spherical
cell aggregates formation when added to MvLu1 and P19
cells [31,46,48]. A dynamic system to assay cell aggrega-
tion to CCN2/CTGF was developed by using anti-Flag
conjugated agarose beads pre-incubated with recombinant
CCN2/CTGF enriched medium and added to sub-
confluent P19 cells cultured for 24 h. This experiment
aimed to check the local action of CCN2/CTGF on P19
cells aggregation. It was observed none or few P19 cells
interacting with untreated beads. In contrast, many P19
cells were detected surrounding and adhering to CCN2/
CTGF-treated beads. The attached cells displayed mor-
phological changes varying from a flat to an elongated
shape reminiscent from the bead shape [46,48]. In this
study, Boyden chamber assay indicated CCN2/CTGF as a
chemoattractive molecule increasing the migration of P19
cells up to three folds [48]. In the same study, a new ap-
proach was used to measure the adhesive potential of
CCN2/CTGF and to compare it with well known adhesive
molecules. Using optical tweezers, we obtained quantita-
tive parameters to evaluate molecular adhesiveness. Our
data supported the CCN2/CTGF chemotactic property,
although it is not an adhesive molecule for P19 cells.
From innocent to guilty: CCN2/CTGF as a key molecule in
metastasis
The link between CCN2/CTGF and cell adhesion is
based on protein interactions in extracellular domain,stimulus in extracellular matrix production and upregula-
tion of adhesion pathways, but not due an own adhesive
property [48]. These adhesion pathways are triggered by
Integrins or MAPK activation resulting in cell attachment
and detachment [50]. Knockdown of CCN2/CTGF in
TW2.6 cells was shown to reduce tumor formation and
decrease E-cadherin expression in xenotransplanted tu-
mors [51]. Although there has been a huge variety of re-
search conducted on the harmful effects of increasing
levels of CCN2/CTGF, the understanding of its patho-
physiology and possible modulators remain unclear.
Deendooven et al. detected CCN2/CTGF levels in plasma,
serum or urine in patients with fibrotic complications in
consequence of hepatitis, diabetes and renal transplant-
ation [52]. The high levels of CCN2/CTGF in these secre-
tions suggested that it is a relevant biomarker of disorders.
Furthermore, there are no efficient treatments for most
disorders where the upregulation of CCN2/CTGF is
involved.
Taking into account the role of CCN2/CTGF on cell
migration process, the expression of CCN2/CTGF has
been correlated to metastasis progression. Overexpres-
sion of CCN2/CTGF was associated with invasiveness
potential of the lung adenocarcinoma cells [53], and
osteolytic metastasis of breast cancer [54]. Interestingly,
CCN2/CTGF enhanced the motility of breast cancer
cells by an integrin-α5β3-ERK1/2-phosphorylation [42].
In chondrosarcoma cells, CCN2/CTGF enhances cell
migration by matrix metalloproteinase-13 upregulation
through integrin α5β3 [55] and in gastric cancer through
downregulation of E-cadherin by NF-κB pathway [56].
Curiously, neutralizing anti-CCN2/CTGF antibody attenu-
ated metastasis pancreatic cancer [57]. In cancer and in
metastasis, the role of CCN2/CTGF seems to be the same.
In the last years, the number of studies showing CCN2/
CTGF involved in migration and metastasis has increased.
The treatment of patients with metastasis is not efficient.
For this reason, the occurrence of metastasis in cancer is
an important issue nowadays, and CCN2/CTGF could be
an important target for its attenuation or prevention.
CCN2/CTGF a challenge for the future: Where will we go?
In order to develop specific treatments for disorders where
CCN2/CTGF are upregulated, as metastasis, CCN2/CTGF
shutdown by epigenetic modulation may be an effective
strategy. In general, DNA methylation patterns are estab-
lished and modified in response to environmental factors
by DNA methyl-transferases (DNMTs) which inhibits
gene transcription and regulates gene expression [58].
Therefore, inhibition of CCN2/CTGF expression in spe-
cific diseases could be achieved by increasing DNA
methylation of the CCN2/CTGF gene on promoter re-
gion. DNA methylation of the CCN2/CTGF genomic
sequence has already been reported in several cancers
Figure 4 Repression of CCN2/CTGF transcription by
methylation. Antibodies distributed over the membrane of the
liposome vesicle, could be used to recognize target cells as: Ovarian
tumor cells, breast tumor cells or hiperproliferative fibroblast during
wound healing. It might allow more specificity in the blockage. The
DNA methyl-transferase enzyme linked to specific primer for CCN2/
CTGF promoter region is located inside the lipofection body. The
rational allow us to imagine that CCN2/CTGF gene hipermethylation
will promote its downexpression. CCN2/CTGF Primers forward 5′
GAGACAGCCAGTGCGACTC 3′ Reverse 3′ CGGGCTGTCGTCTCGG 5′.
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lation contributing for gene silencing had never been
described. The mechanisms of CCN2/CTGF expression
remain unknown. The delivery of DNA methyl-transferase
enzyme linked to specific primer for CCN2/CTGF in pro-
moter region directs to the target cell, through antibodies
that recognize specifically target cell, could be explored as
a way to silence CCN2/CTGF. This blockage-pack would
have a DNMT linked to CCN2/CTGF primers (Forward
and Reverse sense) designed to its promoter region.
DNMT would hypermethylate the CCN2/CTGF promoter
region and CpG islands will be increased leading to
CCN2/CTGF donwregulation (Figure 4). A homozygous
deletion of CCN2/CTGF at human chromosome 6q23.2
by hypermethylation could be used or breast cancer cells,
for example. It would be useful to block its expression and
then decrease cancer metastasis. Our proposed DNA
methylation strategy on promoter region of CCN2/CTGF
gene to control its expression would certainly control all
chain reactions triggered by this growth factor. We hope
that in the future, alike strategies that could be used to
block target gene transcription and, consequently, inhibit
its migration and adhesion by preventing several disorders
as metastasis, fibrosis or tissue remodeling.Competing interests
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